IMR Press / JOMH / Volume 18 / Issue 5 / DOI: 10.31083/j.jomh1805107
Open Access Review
Changes in the treatment landscape for metastatic urothelial cancer: current therapy and future directions
Show Less
1 Department of Internal Medicine, Chungnam National University Hospital, 35015 Daejeon, Republic of Korea
*Correspondence: cymed@cnu.ac.kr (Hyo Jin Lee)
J. Mens. Health 2022, 18(5), 107; https://doi.org/10.31083/j.jomh1805107
Submitted: 1 November 2021 | Accepted: 20 December 2021 | Published: 6 May 2022
Copyright: © 2022 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.
Abstract

Despite the development of several new drugs, cisplatin-containing chemotherapy remains the standard frontline option for advanced urothelial carcinoma (UC). Since the cisplatin-based regimen became the standard therapy for metastatic UC, there have been few advances in chemotherapy, until recently. A better understanding of molecular pathobiology of UC and advances in cancer immunology have led to a sharp increase in clinical trials for metastatic UC with the rapidly changing systemic treatment for this disease. This review summarizes current chemotherapy and immunotherapy for metastatic UC, as well as novel agents and ongoing trials.

Keywords
urothelial carcinoma
cytotoxic chemotherapy
immunotherapy
targeted agent
antibody-drug conjugate
biomarker
Share
Back to top